CARDS: Difference between revisions
Jump to navigation
Jump to search
←Redirected page to Collaborative Atorvastatin (Lipitor) And Diabetes Study |
Rim Halaby (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{LDL}} | |||
{{CMG}} | |||
'''Click [[xxx|here]] to download slides for CARDS.''' | |||
==Overview== | |||
Atorvastatin 10 mg daily significantly reduced the occurrence of primary end-point of MACE and secondary end-points of CHD events, coronary revascularizations and stroke during a median follow-up of 3.9 years in 2838 patients with type 2 diabetes and LDL < 160 mg/dL. Trial was stopped 2 years earlier than expected<ref name="pmid15325833">{{cite journal| author=Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al.| title=Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. | journal=Lancet | year= 2004 | volume= 364 | issue= 9435 | pages= 685-96 | pmid=15325833 | doi=10.1016/S0140-6736(04)16895-5 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15325833 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15739976 Review in: ACP J Club. 2005 Mar-Apr;142(2):29] </ref>. | |||
==References== | |||
{{Reflist|2}} | |||
{{Lipopedia}} | |||
[[Category:Lipopedia]] | |||
[[Category:Clinical trials]] | |||
Latest revision as of 04:15, 29 September 2014
|
Low Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
CARDS On the Web |
|
American Roentgen Ray Society Images of CARDS |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Click here to download slides for CARDS.
Overview
Atorvastatin 10 mg daily significantly reduced the occurrence of primary end-point of MACE and secondary end-points of CHD events, coronary revascularizations and stroke during a median follow-up of 3.9 years in 2838 patients with type 2 diabetes and LDL < 160 mg/dL. Trial was stopped 2 years earlier than expected[1].
References
- ↑ Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ; et al. (2004). "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial". Lancet. 364 (9435): 685–96. doi:10.1016/S0140-6736(04)16895-5. PMID 15325833. Review in: ACP J Club. 2005 Mar-Apr;142(2):29